Company Overview and News

1
Bone Therapeutics: In (Re)Search For Money

2018-01-31 seekingalpha
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.
Upvote Downvote

 
Takeda's Offer On Tigenix - Good Deal Or Not?

2018-01-12 seekingalpha
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.
Upvote Downvote

3
Bone Therapeutics: Deeply Undervalued Early Stage Biotech

2017-10-31 seekingalpha
A shot on three multibillion-dollar markets with highly unmet medical needs and very little competition (in two of the three markets).
Upvote Downvote

1
The Alliance for Regenerative Medicine Announces Presenting Companies at 2017 Cell & Gene Meeting on the Mesa

2017-07-19 marketwired
WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.
Upvote Downvote

 
The Alliance for Regenerative Medicine Releases Agenda for Fifth Annual Cell & Gene Therapy Investor Day

2017-04-06 marketwired
WASHINGTON, DC--(Marketwired - Apr 6, 2017) -  The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming fifth annual Cell & Gene Therapy Investor Day, taking place April 27, 2017 in Boston, MA. This event, co-hosted by Piper Jaffray and held in partnership with Cowen and Company is the only investor conference specifically focused on cell and gene therapies, offering exclusive access to the field's most promising companies.
Upvote Downvote

 
The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Fifth Annual Cell & Gene Therapy Investor Day

2017-02-02 marketwired
This one-day program taking place April 27 is the only investor conference specifically focused on cell and gene therapies, providing institutional, strategic and venture investors with access to 30+ of the field's most promising companies
Upvote Downvote

 
Bone Therapeutics Taps a New CEO, Drops Plan to Initiate Cell Therapy Trial in the U.S.

2016-11-08 biospace
Thomas Lienard, Chief Executive Officer, and Wim Goemaere, Chief Financial Officer, will host a conference call today at 14:00 CET / 13:00 BST / 08:00 EDT.
Upvote Downvote

 
Bone Therapeutics's Longtime CEO to Step Down for Personal Reasons

2016-10-11 devicespace
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in bone fracture repair, fracture prevention and spinal fusion, today announces that Enrico Bastianelli has informed the Board of his intention to stand down as Chief Executive Officer after 10 years in the role for personal reasons. Thomas Lienard, the current Chief Business Officer, will become Interim CEO of the Company, working closely with Wim Goemaere, Chief Financial Officer, and the rest of the management team.
Upvote Downvote

 
Bone Therapeutics CEO to Step Down for Personal Reasons

2016-10-11 biospace
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in bone fracture repair, fracture prevention and spinal fusion, today announces that Enrico Bastianelli has informed the Board of his intention to stand down as Chief Executive Officer after 10 years in the role for personal reasons. Thomas Lienard, the current Chief Business Officer, will become Interim CEO of the Company, working closely with Wim Goemaere, Chief Financial Officer, and the rest of the management team.
Upvote Downvote

 
Bone Up On First Osteoporosis Data

2016-09-18 seekingalpha
The first data on Bone Therapeutics’ (OTC:BNZPF) cell therapy Preob in severe osteoporosis, showing that the cells accumulate in the bone as hoped, is the initial step towards showing that it can actually spur bone growth.
Upvote Downvote

 
iSTAR Medical Strengthens Board With Two Senior Appointments

2016-06-28 prnewswire
iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the appointment of Martin Wax, M.D. and Marc Nolet de Brauwere to the Board of Directors.
Upvote Downvote

 
Is It Time To Invest In Stem Cell Biotechs?

2016-06-03 seekingalpha
Stem cell therapies hold the promise to cure chronic diseases that currently cause a heavy economic burden on society but clinical development has been decades in the making.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...